Heller experts participate in Mass. hearings on health care cost trends

March 16, 2010

Today, Thursday, and Friday, Heller School health care experts are participating in public hearings on health care cost trends sponsored by the Massachusetts Department of Health and Human Services. The Division of Health Care Finance & Policy in collaboration with the Office of the Attorney General is holding these annual hearings regarding health care costs, provider and insurer costs, and strategies to mitigate these cost trends.

Stuart Altman, the Sol C. Chaikin Professor of National Health Policy, will serve as both expert witness and moderator. On Thursday, Altman will moderate a discussion on “Understanding Cost Drivers in the Health Care System.” Friday morning, Altman will be an expert witness on “Market Reform Considerations to Reduce the Growth in Healthcare Spending.”

Stan Wallack, professor and executive director of the Schneider Institutes for Health Policy at the Heller School, will moderate a discussion Thursday morning on “Creating the Framework for High PerformingOrganizations.”

Altman, Wallack, and Cindy Thomas, Associate Research Professor at the Schneider Institute at Heller, also wrote one of the preliminary reports to inform the discussion, and contributed to two other reports provided at the hearings.

Click here for more information and a detailed agenda. Read the preliminary reports here.

Media Contact

The Heller School welcomes media inquiries on this and all other news items. Email  Laura Gardner or call 781-736-4204.

Also in the News

Anita Hill Gave the Oscars After-Party Scene Its Most Meaningful Moment

February 26, 2019

Vogue writes about Anita Hill attending the Oscars 2019 After-Party.

How Can Asia Unleash the Potential of Youth?

February 26, 2019

In the Diplomat, read about Pharady Kao, MA SID'20, her life in Cambodia and why youth like her want their voices heard.

FDA takes fresh look at whether opioids are effective for chronic pain

February 26, 2019

In the Washington Post, Andrew Kolodny says five years later, we don’t have the studies and another FDA commissioner says, ‘We’re going to do the studies.’

News Archive →